Skip to main content
Premium Trial:

Request an Annual Quote

Blue Shield of California Issues Positive Coverage Policy for Veracyte's Afirma GEC

NEW YORK (GenomeWeb) – San Francisco-based Veracyte today announced that Blue Shield of California has issued a positive coverage policy for the firm's Afirma Gene Expression Classifier.

The Afirma GEC employs a 142-gene signature to identify benign thyroid nodules in patients whose fine needle aspiration biopsies are deemed indeterminate following traditional cytopathology review and thus face a potentially unnecessary diagnostic surgery. Blue Shield of California, one of the largest Blue Cross Blue Shield-affiliated organizations, classified the genomic test as medically necessary for use in identifying those patients.

The decision makes the thyroid cancer test available to approximately 3 million people, effective immediately. The test is now available to more than 140 million people, the firm said in a statement. Additionally, the Hawaii Medical Services Association, also affiliated with BCBS, published a draft policy indicating it intends to cover Veracyte's genomic test beginning in February 2015.

Blue Shield of California joins Cigna, Humana, Aetna, UnitedHealthcare, and the federal Medicare program in offering coverage for the test. 

"These new policies further underscore the value of the Afirma GEC — proven in multiple, peer-reviewed, published studies — in helping patients with thyroid nodules avoid unnecessary surgery," Bonnie Anderson, CEO of Veracyte, said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.